Assay Designs(TM), Inc. Announces Agreement with Abnova Corp.... ( ANN ARBOR Mich. Nov. 5 /- Assay D...)

Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan

Date:11/5/2008

ANN ARBOR, Mich., Nov. 5 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life science and translational research markets, has announced a strategic agreement with Abnova Corporation of Taiwan. The agreement enables Assay Designs to distribute approximately 3,200 of Abnova's highly characterized monoclonal antibodies to their U.S. and Canadian customers. This major product addition expands Assay Designs' current product portfolio to include over 5,300 reagents for important research areas such as cell signaling, cellular stress, neuroscience, and inflammation.

"This new partnership with Abnova expands our current product portfolio tremendously with high quality monoclonals for a broad range of applications and research areas," stated Dan Calvo, CEO of Assay Designs. "Abnova's capacity to develop and produce antibodies is very complementary to our current antibody and immunoassay businesses, and affords our customer base easy access to their most highly characterized monoclonals for applications such as ELISA, immunohistochemistry, and immunofluorescence as well as western blotting."

Abnova's mission is to be the world's largest antibody distributor. They have the capacity of generating 500 mouse monoclonal antibodies and 500 rabbit polyclonal antibodies per month. "We are very pleased to be collaborating with Assay Designs on broadening the exposure and accessibility of Abnova antibody and proteins products in the research market," states Wilbur Huang, CEO of Abnova. "Moreover, Assay Designs' expertise in immunoassay and system development highly complements Abnova's capability in industrial-scale antibody manufacturing based on 'one gene one antibody' translation of the human genome. Assay Designs and Abnova will work closely together to realize next generation of analytical products which will accelerate the translational research in the proteomics era."

About Assay Designs, In
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
2. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
3. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
4. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
5. CISBIO Bioassays Launches Chromoa(TM) Chromogranin A ELISA Kit
6. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
7. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
8. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
9. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
10. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
11. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay

Post Your Comments:

Assay Designs(TM), Inc. Announces Agreement with Abnova Corp....( ANN ARBOR Mich. Nov. 5 /- Assay D...)